Ophthotech Corp (NASDAQ:OPHT)

Data as of Jan 26
 -0.14 / -0.25%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Ophthotech Corp. operates as a biopharmaceutical company. It focuses on discovering, developing and commercializing novel therapeutics to treat diseases of the eye. The company develops therapies for age-related macular degeneration. Its product candidates include Fovista Anti platelet derived growth factor Therapy, Zimura Anti-Complement and Aptamer Technology. The company was founded on January 5, 2007 by David R. Guyer and Samir Chandrakant Patel and is headquartered in New York, NY.

Contact Information

Ophthotech Corp.
One Penn Plaza
New York New York 10119
P:(212) 845-8200
Investor Relations:
(212) 845-8231



Individual stakeholders43.07%
Mutual fund holders38.85%
Other institutional13.40%

Top Executives

David R. GuyerChairman & Chief Executive Officer
Samir Chandrakant PatelVice Chairman & President
Evelyn M. HarrisonChief Operating Officer
Michael G. AtiehTreasurer, EVP, Chief Financial & Business Officer
Richard L. BeckmanChief Medical Officer

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.